Overview Dividends

(RNA) Avidity Biosciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05370A1088

Antibody-Oligonucleotide Conjugates, Delpacibart Etedesiran, Delpacibart Braxlosiran, Delpacibart Zotadirsen

RNA EPS (Earnings per Share)

EPS Growth (3Y CAGR): -47.67%
EPS Trend (3Y Correlation): -60.8%

RNA Revenue

Revenue Growth (3Y CAGR): 17.28%
Revenue Trend (3Y Correlation): 6.7%

Risk via 10d forecast
Volatility	74.0%
Value at Risk 5%th	102%

Reward
Sharpe Ratio	0.83
Alpha Jensen	37.04

Character
Hurst Exponent	0.399
Beta	0.905

Drawdowns 3y
Max DD	81.01%
Mean DD	31.93%

Description: RNA Avidity Biosciences November 07, 2025

Avidity Biosciences (NASDAQ:RNA) is a San-Diego-based biopharma that develops antibody-oligonucleotide conjugates (AOCs), marrying monoclonal-antibody targeting with RNA-based gene-silencing to reach disease mechanisms that conventional biologics cannot.

Its current pipeline includes three registrational-stage programs: Delpacibart etedesiran (Phase 3 for myotonic dystrophy type 1), Delpacibart braxlosiran (Phase 1/2 for facioscapulohumeral muscular dystrophy) and Delpacibart zotadirsen (Phase 2 EXPLORE44 open-label extension for Duchenne muscular dystrophy). In addition, Avidity is advancing precision-cardiology AOCs such as AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for PRKAG2-related cardiomyopathy.

As of Q3 2024, the company reported cash and equivalents of roughly $210 million, giving it an estimated 12-month runway at current burn rates (~$20 million per quarter). The RNA-therapeutics market is projected to grow at a 10-12% CAGR through 2030, driven by expanding FDA approvals for oligonucleotide drugs and increasing payer acceptance of rare-disease therapies-factors that could lift Avidity’s valuation if its Phase 3 readout is positive.

For a deeper, data-driven look at RNA’s risk-adjusted upside, you might explore the analyst tools on ValueRay.

RNA Stock Overview

Market Cap in USD	10,260m
Sub-Industry	Biotechnology
IPO / Inception	2013-06-28
Return 12m vs S&P 500	30.8%
Analyst Rating	4.60 of 5

RNA Dividends

Currently no dividends paid

RNA Growth Ratios

CAGR	78.38%
CAGR/Max DD Calmar Ratio	0.97
CAGR/Mean DD Pain Ratio	2.45
Current Volume	3018.3k
Average Volume	5422.4k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-455.7m TTM) > 0 and > 6% of Revenue (6% = 643.7k TTM)

FCFTA -0.37 (>2.0%) and ΔFCFTA -24.93pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 10.4k% (prev 11.7k%; Δ -1345 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.36 (>3.0%) and CFO -490.0m <= Net Income -455.7m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 9.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (129.6m) change vs 12m ago 21.22% (target <= -2.0% for YES)

Gross Margin 78.92% (prev 89.73%; Δ -10.81pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 0.79% (prev 0.79%; Δ 0.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -7.82 (EBITDA TTM -519.5m / Interest Expense TTM -66.9m) >= 6 (WARN >= 3)

Altman Z'' -6.95

(A) 0.81 = (Total Current Assets 1.25b - Total Current Liabilities 135.1m) / Total Assets 1.37b

(B) -0.85 = Retained Earnings (Balance) -1.17b / Total Assets 1.37b

(D) -6.61 = Book Value of Equity -1.16b / Total Liabilities 176.3m

Total Rating: -6.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 29.53

1. Piotroski 0.0pt = -5.0

2. FCF Yield -5.53% = -2.77

3. FCF Margin data missing

4. Debt/Equity 0.00 = 2.50

5. Debt/Ebitda 0.46 = 2.34

6. ROIC - WACC (= -39.87)% = -12.50

7. RoE -33.45% = -2.50

8. Rev. Trend 6.68% = 0.50

9. EPS Trend -60.79% = -3.04

What is the price of RNA shares?

As of November 13, 2025, the stock is trading at USD 70.82 with a total of 3,018,294 shares traded.
Over the past week, the price has changed by +1.46%, over one month by +44.65%, over three months by +53.19% and over the past year by +51.55%.

Is Avidity Biosciences a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Avidity Biosciences (NASDAQ:RNA) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 29.53 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RNA is around 82.12 USD . This means that RNA is currently undervalued and has a potential upside of +15.96% (Margin of Safety).

Is RNA a buy, sell or hold?

Avidity Biosciences has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy RNA.

Strong Buy: 9
Buy: 6
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the RNA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	73.7	4%
Analysts Target Price	73.7	4%
ValueRay Target Price	92.4	30.5%

RNA Fundamental Data Overview November 12, 2025

Market Cap USD = 10.26b (10.26b USD * 1.0 USD.USD)
P/S = 956.309
P/B = 5.4047
Beta = 0.905
Revenue TTM = 10.7m USD
EBIT TTM = -522.6m USD
EBITDA TTM = -519.5m USD
Long Term Debt = 5.13m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.92m USD (from shortTermDebt, last quarter)
Debt = 5.13m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -238.8m USD (from netDebt column, last quarter)
Enterprise Value = 9.08b USD (10.26b + Debt 5.13m - CCE 1.18b)
Interest Coverage Ratio = -7.82 (Ebit TTM -522.6m / Interest Expense TTM -66.9m)
FCF Yield = -5.53% (FCF TTM -502.7m / Enterprise Value 9.08b)
FCF Margin = -4685 % (FCF TTM -502.7m / Revenue TTM 10.7m)
Net Margin = -4248 % (Net Income TTM -455.7m / Revenue TTM 10.7m)
Gross Margin = 78.92% ((Revenue TTM 10.7m - Cost of Revenue TTM 2.26m) / Revenue TTM)
Gross Margin QoQ = 78.84% (prev 100.0%)
Tobins Q-Ratio = 6.63 (Enterprise Value 9.08b / Total Assets 1.37b)
Interest Expense / Debt = 7.61% (Interest Expense 391.0k / Debt 5.13m)
Taxrate = 21.0% (US default 21%)
NOPAT = -412.9m (EBIT -522.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.26 (Total Current Assets 1.25b / Total Current Liabilities 135.1m)
Debt / Equity = 0.00 (Debt 5.13m / totalStockholderEquity, last quarter 1.19b)
Debt / EBITDA = 0.46 (negative EBITDA) (Net Debt -238.8m / EBITDA -519.5m)
Debt / FCF = 0.47 (negative FCF - burning cash) (Net Debt -238.8m / FCF TTM -502.7m)
Total Stockholder Equity = 1.36b (last 4 quarters mean from totalStockholderEquity)
RoA = -33.29% (Net Income -455.7m / Total Assets 1.37b)
RoE = -33.45% (Net Income TTM -455.7m / Total Stockholder Equity 1.36b)
RoCE = -38.21% (EBIT -522.6m / Capital Employed (Equity 1.36b + L.T.Debt 5.13m))
RoIC = -30.30% (negative operating profit) (NOPAT -412.9m / Invested Capital 1.36b)
WACC = 9.57% (E(10.26b)/V(10.27b) * Re(9.57%) + D(5.13m)/V(10.27b) * Rd(7.61%) * (1-Tc(0.21)))
Discount Rate = 9.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 30.55%
Fair Price DCF = unknown (Cash Flow -502.7m)
EPS Correlation: -60.79 | EPS CAGR: -47.67% | SUE: -1.06 | # QB: 0
Revenue Correlation: 6.68 | Revenue CAGR: 17.28% | SUE: 2.21 | # QB: 1

Additional Sources for RNA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle